Collecting duct carcinoma (CDC) of the kidney is a rare and aggressive malignant tumor arising from the distal collecting tubules which has been shown to have a poor response to several kinds of systemic therapy. We present a case of metastatic CDC that responded favorably to a multiple tyrosine kinase inhibitor, sunitinib, achieving a partial response in both lung and skeletal metastases. To our knowledge, this is the first report showing therapeutic activity of sunitinib against CDC. Considering these findings, it would be worthwhile prospectively investigating the role of multiple tyrosine kinase inhibitors, particularly sunitinib, in the management of metastatic CDC.
CITATION STYLE
Tazi, E. M., Essadi, I., Tazi, M. F., Ahellal, Y., M’rabti, H., & Errihani, H. (2011). Retraction Note: metastatic collecting duct carcinoma of the kidney treated with Sunitinib. World Journal of Surgical Oncology, 9(1). https://doi.org/10.1186/1477-7819-9-136
Mendeley helps you to discover research relevant for your work.